Shanghai Singlera Genomics, a genetic early cancer screening company, has completed nearly RMB1 billion yuan in Series B financing. This round of financing was led by the CICC Qide Innovative Biomedicine Fund under CICC Capital, and jointly led by DT Capital Partners and Furong Investment. Huamei International, Leading Capital, Wuxi Gold Investment, FutureX Capital, Shanghai […]

CICC Capital Leads RMB1 Billion Round In Cancer Screening Firm comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.

Visit the original source and full text: China Money Network